Document Detail

Dialysate CA125 levels in children on continuous peritoneal dialysis.
MedLine Citation:
PMID:  16133054     Owner:  NLM     Status:  MEDLINE    
This prospective study was conducted to assess dialysate cancer antigen 125 (dCA125) levels in pediatric peritoneal dialysis (PD) patients and to investigate whether it exhibits any alterations during or after recovery from peritonitis, and also to analyze the relationships between dCA125 and age, duration of PD treatment, peritonitis incidence, time passed since the last episode of peritonitis, PD prescription parameters, and peritoneal transport parameters. Forty-seven standardized 4-h peritoneal equilibration tests (PET) were performed in 38 children (mean age 11.6+/-4.7 years) on PD (duration 20.9+/-14.3 months). Thirty-two of the patients were in stable condition at the time of PET (stable group). Six patients were included in the study only during a peritonitis episode, and two of the stable patients were reevaluated during a peritonitis episode afterwards (peritonitis group). Seven out of a total of eight patients with acute peritonitis were reexamined after recovery (recovery group). CA125 levels were measured in 188 samples at 0-, 1-, 2-, and 4-h dwells. Peritoneal appearance rates (AR) were calculated. Mean dCA125 (4 h) and AR CA125 values were 5.6+/-5.3 U/ml [median 4.15 U/ml/4 h (range 0.5-25.9)] and 50.1+/-45.6 U/min/1.73 m2[median 37.91 U/ml/1.73 m2 (range 3.61-223.39)]. AR CA125 levels did not correlate with age, PD duration, peritonitis incidence, time passed since the last peritonitis episode, exchange volume used per m2 per day, or peritoneal transport properties in the stable patients' group. Although stable patients using hypertonic PD solutions (n=16) had slightly lower AR CA125 levels (p=0.04), multivariate analysis showed no influence of hypertonic dextrose solutions on mesothelial CA125 secretion (p=0.4). During acute peritonitis, CA125 concentrations showed a reversible threefold increase [AR CA125: stable 37.9 vs. peritonitis 101.2 U/ml/1.73 m2 (p=0.001)]. No difference could be found between the stable group and the recovery group. We conclude that changes in the peritoneal mesothelial cell mass cannot be assessed by determining CA125 in a cross-sectional way and that longitudinal determinations could be more valuable in the follow-up of patients.
Pinar Turhan; Lale Sever; Salim Caliskan; Ozgur Kasapcopur; Ayse Sever; Munire Hacibekiroglu; Nil Arisoy
Related Documents :
21167404 - Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous ...
3095914 - Abo blood groups, rhesus types, and colorectal adenocarcinoma. a retrospective study of...
3341344 - Listeria monocytogenes peritonitis.
15942784 - Twenty years' pediatric chronic peritoneal dialysis in uruguay: patient and technique s...
1387434 - Urinary c3dg and c5b-9 indicate active immune disease in human membranous nephropathy.
23548674 - The relationship of nt-probnp and dialysis parameters with outcome of incident haemodia...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2005-08-20
Journal Detail:
Title:  Pediatric nephrology (Berlin, Germany)     Volume:  20     ISSN:  0931-041X     ISO Abbreviation:  Pediatr. Nephrol.     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-10-06     Completed Date:  2006-03-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8708728     Medline TA:  Pediatr Nephrol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1615-21     Citation Subset:  IM    
Department of Pediatric Nephrology, SSK Bakirkoy Maternity and Children's Hospital, Atakoy 7-8 mah. A/25-B D:99, 34750 Bakirkoy, Istanbul, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
CA-125 Antigen / analysis*
Child, Preschool
Hemodialysis Solutions / chemistry*
Peritoneal Dialysis, Continuous Ambulatory* / adverse effects
Peritoneum / metabolism
Peritonitis / etiology,  metabolism
Reg. No./Substance:
0/CA-125 Antigen; 0/Hemodialysis Solutions

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Glycation free adduct accumulation in renal disease: the new AGE.
Next Document:  Therapeutic total plasma exchange in a child with neuroblastoma-related anti-Hu syndrome.